Clinical Trials

300383: Phase 3 Study of IDRX-42 (GSK6042981) vs Sunitinib in Participants with Metastatic and/or Unresectable GIST after Imatinib

Link : a href="https://www.clinicaltrials.gov/ct2/show/NCT07218926">https://www.clinicaltrials.gov/ct2/show/NCT07218926
Status : RECRUITING
Population : 2nd line GIST
Description : IDRX-42 vs. sunitinib monotherapy. No crossover.
PI : A. Razak
Centers Opened : PMH
Phase : III
IIST/Pharma : Pharma